In October 2022, the EDPB launched a public consultation on the targeted update of paragraph 73 of the 9/2022 Guidelines on personal data breach notification under the GDPR. Similar to the principles set out in the Working Party 250 Guidelines on personal data breach notification under Regulation 2016/679 (revised in 2018), the EDPB only introduced a major update to data breach notification rules applicable to non-EU companies subject to GDPR.
Data breach notification for EU companies
For a data breach to be reported by a Controller or Processor established in the EU, the EDPB did not…
Click here to view the February 2023 edition of The Meeting Place
We are launching a new study into Equality, Diversity & Inclusion (ED&I) practices within the UK Life Sciences sector. This important research will help to inform our thinking as we develop and implement an ED&I strategy for the sector that promotes best practices.
We want to invite you to take a short survey to help provide an evidence base for the upcoming report. - https://www.surveymonkey.co.uk/r/Z72D2JS
The survey closes on 24 February 2023 and takes approximately just 7 minutes to complete.
We’ll inform you about the results as soon as they are ready by sending you a copy of…
MAXION THERAPEUTICS
Maxion Therapeutics’ $16 million Series A to drive antibody development for previously untreatable ion channel and GPCR-driven diseases
• Investor syndicate comprised of LifeArc Ventures, Monograph Capital and BGF
• Funding will enable development of antibody drugs against ion channels and G-protein-coupled receptors (GPCRs) using proprietary KnotBody® platform, to overcome challenges with this target class
• …
Scientists at Macomics and University of Edinburgh Map Out the Discoveries of a New Class of Tumour Associated Immune Cells Revealing Opportunities to Develop Novel Cancer Treatments
• Publication in Nature Reviews Cancer based on data gained over 50 years of discovery research in the area of macrophage biology
• Reveals future prospects for developing precision medicines to modulate macrophages for the treatment of cancer by targeting tumour associated macrophage (TAMs) in the tumour microenvironment (TME)
Edinburgh and Cambridge, UK, 17 February 2023 – The founding scientists behind…
We are delighted to announce that we have entered into a Strategic Partnership for the Development and cGMP Manufacturing Services for Vaccitech’s Adenoviral Vector programme. Pharmaron will become a key part of Vaccitech’s manufacturing network to support novel T cell immunotherapeutics and vaccines from its proprietary ChAdOx1 viral vector platform.
The partnership began last year with the technology transfer of a Vaccitech proprietary manufacturing process into Pharmaron’s state-of-the-art Liverpool viral development and GMP manufacturing facilities. This will enable Pharmaron to support…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR STRENGTHENS COLLABORATION WITH TOP 5 GLOBAL PHARMACEUTICAL PARTNER THROUGH ADDITIONAL FORMULATION AGREEMENT
- Eighth new technology partnership with major pharmaceutical and biotech companies since IPO
Cambridge, UK, 14 February 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an additional formulation study agreement with its top five global pharmaceutical partner, building on a collaboration formed in 2022.
Under the terms…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR GRANTED PATENTS IN INDIA AND THE UNITED STATES PROTECTING PROPRIETARY FORMULATIONS OF DIFFERENTIATED BIOPHARMACEUTICAL PRODUCTS
- Patents further strengthen Group’s extensive patent portfolio protecting its proprietary diabetes portfolio and demonstrate potential of innovative Arestat™ technology in development of enhanced formulations of high value biologics
Cambridge, UK, 16 February 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to announce…
The new MagSi-DNA FFPE kit from AMSBIO enables quick and easy isolation of genomic DNA (gDNA) from mammalian formalin-fixed paraffin-embedded (FFPE) tissue or cell samples.
Developed using proprietary magnetic bead technology – the MagSi-DNA FFPE kit can be used for manual and automated isolation of gDNA from mammalian FFPE tissue or cell samples.
The kit does not require traditional phenol/chloroform extraction or alcohol precipitation steps and also eliminates the need for repeated centrifugation, vacuum filtration or column separations. As a result, following paraffin removal and lysis…
India stands as a promising power in the pharmaceutical industry
The Asian country is growing the pharmaceutical industry at an unprecedented rate and DIVERSA wants to join the challenge! India is currently experiencing a significant economic growth. In fact, although in the past it was not among the top 5 main world economic powers, it is estimated that it will occupy the third position by 2030. This forecast is based on its important role in the global pharmaceutical industry, among other reasons. DIVERSA has had the opportunity to meet relevant players in the Indian biotech sector and to…